The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Defining Cognitive Phenotypes of Parkinson’s Disease, 2011The Relationship Between Cognitive Phenotypes of PD with Visual Hallucinations and 5HT2A Receptors in the Inferotemporal Cortex
Objective/Rationale:
The project aims to understand the mechanisms underlying cognitive deficits that are associated with visual hallucinations (VH) in Parkinson’s disease (PD). We have previously... -
MJFF Research Grant, 2009Clinicogenetic Studies of LRRK2 G2019S in Tunisia
Objective/Rationale:
Parkinson’s disease (PD) is a prevalent, heterogeneous disorder with a complex, multifactorial etiology. In Tunisia, North Africa, the burden of genetically-defined LRRK2 G2019S... -
PD Subtypes, 2007Evaluating Novel Predictors of Parkinson's Disease Progression
How the symptoms of Parkinson’s disease progress varies from patient to patient, and it is hard to predict which patients will progress more quickly than others. One way to figure this out is to look...
-
MJFF Research Grant, 2011Assessing and Diagnosing Anxiety in Patients with Parkinson's Disease
Promising Outcomes of Original Grant:
A previous MJFF sponsored study showed that the available anxiety questionnaires are not suitable to assess anxiety in Parkinson’s disease (PD). The different... -
Rapid Response Innovation Awards, 2013Evaluation of Targeted Plasticity Therapy as a Treatment for Motor Dysfunction in Parkinson’s Disease
Objective/Rationale:
Deterioration of motor function is a debilitating symptom of Parkinson’s disease (PD). We have recently developed a novel method that utilizes stimulation of the...
-
Target Validation, 2011Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief
Objective/Rationale:
Endogenous activation of the Delta opioid receptor (DOR) serves as a compensatory mechanism to alleviate Parkinson’s disease (PD) symptoms. However, DOR-mediated convulsions have...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.